Inquiresuppliers

Value Analysis Readiness Review

For medtech and supply companies taking a product to hospital value analysis committees. Practitioners from the seats that decide (value analysis, supply chain, and a nurse or physician who uses the category) score your committee packet the way a committee would. You get the objections they would raise, in their words, and what to fix before the next committee.

About one week · 3 practitioners $3,500 · 5 practitioners $6,000

See example ↓
Your inquiry
Who you want answering

Pick any. Leave blank and we will choose.

We reply within one business day with a scope and a fixed quote. Nothing is owed until you approve it.

Example
Illustrative sampleValue Analysis Readiness Review3 practitioners · delivered in 6 business days

Format is real. Answers are composites, and the companies and products in it are invented. This is replaced by a real, redacted engagement after the first paid project.

The client

A mid-size device company with a new hydrophilic-coated midline catheter. It holds one national GPO innovation contract and has been rejected at 2 of its first 5 hospital committees.

The question

How will a hospital value analysis committee judge our midline against the incumbent, and what in our packet is getting us rejected?

Who answered

  1. 01Value analysis director, 12-hospital health system
  2. 02Supply chain director, regional health system
  3. 03Vascular access nurse (VA-BC), academic medical center

Role and setting only. The client never learns who answered.

The verdict

Ready with changes: 3 of 3The clinical story is strong. The cost story is missing, and that is what is getting you rejected.

Dimension by dimension

Where the practitioners agreed, and what they said.

  • Clinical evidenceAgreeTwo outcome studies help. Committees want one from a US community hospital.
  • Total cost of ownershipAgreeUnit price is 38% above the incumbent and the packet never answers that.
  • Nursing workflowAgreeSame insertion steps. No new training burden.
  • Standardization fitSplitIt depends on whether the system has already standardized on one midline.
  • Supply resilienceSplitA single plant worries supply chain. Nursing does not weigh it.
  • ReimbursementNot separately reimbursed. Irrelevant to the committee.
  • Packet qualityAgreeToo long, written for physicians, no one-page summary.

The objections a committee will raise

  1. What does this cost us per patient, not per unit?

    Value analysis director, 12-hospital systemJUDGMENTAgree 3 of 3

    If the coating cuts line replacements, show me replacements avoided per 100 lines and the dollars. A higher unit price is fine if the math is on page one.

  2. Who else in a system like ours uses it?

    Supply chain director, regional systemJUDGMENTAgree 3 of 3

    The innovation contract gets you in the door. Two named peer hospitals get you a yes. Committees copy each other.

  3. Does it replace our current midline or sit next to it?

    Vascular access nurse, academic medical centerJUDGMENTSplit

    If we are standardized, a second midline is a no unless you replace the first one completely. The packet should offer a full conversion plan.

    The supply chain director disagrees: dual-sourcing for six months is normal. Offer a trial on one unit.

  4. What happens if you have a backorder?

    Supply chain director, regional systemSOURCEDSplit

    The company's public filing names one plant.

Fix list before the next committee

  1. Add a one-page summary written for supply chain and nursing, not physicians.
  2. Add a cost-per-patient model: replacements avoided per 100 lines times the replacement cost.
  3. Offer a 90-day, one-unit trial with a defined success metric.
  4. Name two peer references, with permission.
  5. Add a continuity statement: second source, safety stock, backorder history.

Public-record context, cited, from our database

  • The client's GPO contract: type, award date, term, cited to the award release.
  • The incumbent midline's GPO positions, from public award announcements.
  • Recent committee-relevant guidance in the category, such as INS standards updates, cited.

Estimates and judgments are practitioners' views, not audited figures. No practitioner discussed their own organization's purchases, pricing or contracts. Practitioners were selected by UltraViolet, not by the client, and are not identified to the client.